(Total Views: 612)
Posted On: 11/22/2024 2:26:22 AM
Post# of 155791
Quote:
I may have just missed it but I couldn't find any mention of how often patients in the mCRC trial would be dosed
A little late to the party.
Quote:
TAS-102 and bevacizumab will be administered for three of four weeks in a four-week cycle, and leronlimab (at doses of 350 mg or 700 mg) will be administered weekly.
https://www.cytodyn.com/newsroom/press-releas...n-phase-ii
(7)
(0)
